FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092437923> ?p ?o ?g. }

• W2092437923 endingPage "372" @default.
• W2092437923 startingPage "368" @default.
• W2092437923 abstract "Tumour cells respond to an effective, targeted drug treatment with BRAF, ALK or EGFR kinase inhibitors by inducing a complex network of secreted signals that promote tumour growth, dissemination and metastasis of drug-resistant cancer cell clones, and increase the survival of drug-sensitive tumour cells, potentially contributing to incomplete tumour regression. Targeted kinase inhibitors such as have proved clinically effective in melanoma with BRAF mutations and in lung adenocarcinoma with EGFR mutations or ALK translocations, but drug resistance almost always follows. This study by Joan Massagué and colleagues shows that tumour cells responding to kinase inhibitors induce a complex network of secreted signals that promote tumour growth, dissemination and metastasis of drug-resistant cancer cell clones, and increase the survival of drug-sensitive tumour cells, potentially contributing to incomplete tumour regression. Drug resistance invariably limits the clinical efficacy of targeted therapy with kinase inhibitors against cancer1,2. Here we show that targeted therapy with BRAF, ALK or EGFR kinase inhibitors induces a complex network of secreted signals in drug-stressed human and mouse melanoma and human lung adenocarcinoma cells. This therapy-induced secretome stimulates the outgrowth, dissemination and metastasis of drug-resistant cancer cell clones and supports the survival of drug-sensitive cancer cells, contributing to incomplete tumour regression. The tumour-promoting secretome of melanoma cells treated with the kinase inhibitor vemurafenib is driven by downregulation of the transcription factor FRA1. In situ transcriptome analysis of drug-resistant melanoma cells responding to the regressing tumour microenvironment revealed hyperactivation of several signalling pathways, most prominently the AKT pathway. Dual inhibition of RAF and the PI(3)K/AKT/mTOR intracellular signalling pathways blunted the outgrowth of the drug-resistant cell population in BRAF mutant human melanoma, suggesting this combination therapy as a strategy against tumour relapse. Thus, therapeutic inhibition of oncogenic drivers induces vast secretome changes in drug-sensitive cancer cells, paradoxically establishing a tumour microenvironment that supports the expansion of drug-resistant clones, but is susceptible to combination therapy." @default.
• W2092437923 created "2016-06-24" @default.
• W2092437923 creator A5001278624 @default.
• W2092437923 creator A5014840923 @default.
• W2092437923 creator A5023066362 @default.
• W2092437923 creator A5026532416 @default.
• W2092437923 creator A5030544248 @default.
• W2092437923 creator A5055628562 @default.
• W2092437923 creator A5060228803 @default.
• W2092437923 creator A5070267154 @default.
• W2092437923 creator A5070308097 @default.
• W2092437923 creator A5072503541 @default.
• W2092437923 creator A5074681719 @default.
• W2092437923 creator A5078729702 @default.
• W2092437923 date "2015-03-25" @default.
• W2092437923 modified "2023-10-12" @default.
• W2092437923 title "Therapy-induced tumour secretomes promote resistance and tumour progression" @default.
• W2092437923 cites W1965371218 @default.
• W2092437923 cites W1969353942 @default.
• W2092437923 cites W1982972087 @default.
• W2092437923 cites W1985549756 @default.
• W2092437923 cites W1985928174 @default.
• W2092437923 cites W1999025555 @default.
• W2092437923 cites W2016987827 @default.
• W2092437923 cites W2017187984 @default.
• W2092437923 cites W2030440427 @default.
• W2092437923 cites W2032211985 @default.
• W2092437923 cites W2041255253 @default.
• W2092437923 cites W2042141743 @default.
• W2092437923 cites W2042619042 @default.
• W2092437923 cites W2043058822 @default.
• W2092437923 cites W2053473615 @default.
• W2092437923 cites W2055624262 @default.
• W2092437923 cites W2058689904 @default.
• W2092437923 cites W2080534618 @default.
• W2092437923 cites W2081410358 @default.
• W2092437923 cites W2100614336 @default.
• W2092437923 cites W2100969832 @default.
• W2092437923 cites W2102365935 @default.
• W2092437923 cites W2105660237 @default.
• W2092437923 cites W2106391833 @default.
• W2092437923 cites W2106915761 @default.
• W2092437923 cites W2115155255 @default.
• W2092437923 cites W2116731538 @default.
• W2092437923 cites W2116910749 @default.
• W2092437923 cites W2128542677 @default.
• W2092437923 cites W2150626351 @default.
• W2092437923 cites W2151832198 @default.
• W2092437923 cites W2152239989 @default.
• W2092437923 cites W2152393981 @default.
• W2092437923 cites W2158217645 @default.
• W2092437923 cites W2159220884 @default.
• W2092437923 cites W2160982674 @default.
• W2092437923 cites W2168143310 @default.
• W2092437923 cites W2169456326 @default.
• W2092437923 doi "https://doi.org/10.1038/nature14336" @default.
• W2092437923 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4507807" @default.
• W2092437923 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25807485" @default.
• W2092437923 hasPublicationYear "2015" @default.
• W2092437923 type Work @default.
• W2092437923 sameAs 2092437923 @default.
• W2092437923 citedByCount "375" @default.
• W2092437923 countsByYear W20924379232015 @default.
• W2092437923 countsByYear W20924379232016 @default.
• W2092437923 countsByYear W20924379232017 @default.
• W2092437923 countsByYear W20924379232018 @default.
• W2092437923 countsByYear W20924379232019 @default.
• W2092437923 countsByYear W20924379232020 @default.
• W2092437923 countsByYear W20924379232021 @default.
• W2092437923 countsByYear W20924379232022 @default.
• W2092437923 countsByYear W20924379232023 @default.
• W2092437923 crossrefType "journal-article" @default.
• W2092437923 hasAuthorship W2092437923A5001278624 @default.
• W2092437923 hasAuthorship W2092437923A5014840923 @default.
• W2092437923 hasAuthorship W2092437923A5023066362 @default.
• W2092437923 hasAuthorship W2092437923A5026532416 @default.
• W2092437923 hasAuthorship W2092437923A5030544248 @default.
• W2092437923 hasAuthorship W2092437923A5055628562 @default.
• W2092437923 hasAuthorship W2092437923A5060228803 @default.
• W2092437923 hasAuthorship W2092437923A5070267154 @default.
• W2092437923 hasAuthorship W2092437923A5070308097 @default.
• W2092437923 hasAuthorship W2092437923A5072503541 @default.
• W2092437923 hasAuthorship W2092437923A5074681719 @default.
• W2092437923 hasAuthorship W2092437923A5078729702 @default.
• W2092437923 hasBestOaLocation W20924379232 @default.
• W2092437923 hasConcept C114851261 @default.
• W2092437923 hasConcept C121608353 @default.
• W2092437923 hasConcept C184235292 @default.
• W2092437923 hasConcept C2776131300 @default.
• W2092437923 hasConcept C2777306565 @default.
• W2092437923 hasConcept C2777658100 @default.
• W2092437923 hasConcept C2779013556 @default.
• W2092437923 hasConcept C2781182431 @default.
• W2092437923 hasConcept C2781230642 @default.
• W2092437923 hasConcept C2994587330 @default.
• W2092437923 hasConcept C502942594 @default.
• W2092437923 hasConcept C54355233 @default.
• W2092437923 hasConcept C71924100 @default.

• next